← Leaderboards
Avinash Desai
Actinium Pharmaceuticals, Inc.
$865,308
Attributed
$1,730,616
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $865.3K · FY2023–24$1M$750K$500K$250K$0
'23
'24
Funding mix
By agency
NIH$1,730,616 · 1
By mechanism
R42$1,730,616 · 1
Top collaborators
- Mark B Geyer2 shared
Most similar at Actinium Pharmaceuticals, Inc.
Same institution · by research overlap
- Mark B Geyer$1,255,803
- Mark S Berger$189,195
Others in their field
Other Rising Stars on “Acute Myelocytic Leukemia”
- Michael E. Roth · Public Health Institute$8,303,012
- Javier Caravaca · University Of California, San Francisco$3,728,080
- Kellie Bickel · Twinstrand Biosciences, Inc.$2,555,383
- Jeevisha Bajaj · University Of Rochester$2,438,184
- Bruno Di Stefano · Baylor College Of Medicine$2,398,360
- Angela Goffredo Fleischman · University Of California-Irvine$2,306,090
Research focus
Acute Myelocytic LeukemiaAdoptedAdoptive Cell TransfersAdultAgedAntibodiesAntibody-Drug ConjugatesAutologousB-Cell Acute Lymphoblastic LeukemiaBehavior TherapyBiodistributionBloodBone MarrowCancer CellCd19 AntigensCd19 GeneCd28 GeneCellsCerebral EdemaCerebrospinal FluidChemotherapyChimeric Antigen ReceptorChimeric Antigen Receptor T CellsActinium
Grant awards (2)
Iomab-ACT: A phase I/II study of 131-I apamistamab targeted lymphodepletion followed by CD19-targeted CAR T-cell therapy for patients with relapsed or refractory B-ALL or DLBCL$865,308
R42 · FY2024 · CA · contact PI
Iomab-ACT: A phase I/II study of 131-I apamistamab targeted lymphodepletion followed by CD19-targeted CAR T-cell therapy for patients with relapsed or refractory B-ALL or DLBCL$865,308
R42 · FY2023 · CA · contact PI